In a cohort of 13 NSCLC patients, the detection rate of point mutations was 62% (n=8) in CTCs and 85% (n=11) in tumor samples, mainly in EGFR, TP53, and FGFR genes. Here, EGFR is linked to non-small cell lung carcinoma.